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COMMENTARY
The new cardiovascular continuum
The cardiovascular continuum
The cardiovascular continuum was first proposed by
Dzau and Braunwald1 in 1991 as a new paradigm for
cardiovascular diseases (Fig). It arose from the realisation
that cardiovascular events such as heart failure and myocar-
dial infarction are really late complications in a chain of
events that starts with a number of cardiovascular risk
factors and continues as a progressive pathogenic process
lasting for decades. Atherosclerosis, myocardial necrosis,
and heart failure cannot be reversed easily, if at all, so
addressing the early components of the continuum—such
as hypertension, diabetes, hyperlipidaemia, and smoking—
offers a chance of arresting the progression of cardiovascu-
lar disease at an early stage. These cardiovascular risk
factors are rarely immediately life-threatening, but because
they are asymptomatic, much effort has been devoted to
screen for them and to modify them by lifestyle changes
and drug treatment.2
Antihypertensive drugs and statins demonstrate the
clinical utility of the cardiovascular continuum concept,
namely, that the correction of cardiovascular risk
factors prevents escalation of cardiovascular disease
and downstream complications including myocardial
infarction, stroke, and ultimately, death.2,3 Angiotensin-
converting enzyme inhibitors, for example, address
different parts of the continuum, including hypertension,
diabetes, left ventricular hypertrophy, remodelling, and
heart failure.1 Research into cardiovascular risk factors
suggests that 80% of cardiovascular events can be
prevented, using either existing drugs or the “polypill”.4
Can we do better by preventing cardiovascular disease
itself?
Obesity and the metabolic syndrome
Hypertension, diabetes, and hyperlipidaemia are all
related to obesity as part of the metabolic syndrome, which
was first identified by Reaven5 nearly two decades ago. In
fact, type 2 diabetes, hyperlipidaemia, and hypertension
all respond to diet and weight control.2,6 Conventionally,
the body mass index (BMI) is used to quantify obesity,
and in Asia, a BMI of 23 is already associated with a
much increased cardiovascular risk. However, waist circum-
ference is more closely associated with cardiovascular
risk than BMI.7 Abdominal obesity results in insulin
resistance and the metabolic syndrome through multiple and
complex mechanisms, such as the active role adipose
tissues play in energy homeostasis and the secretion of
hormones, including leptin, adiponectin, resistin, and
acylation-stimulating protein, that regulate appetite and
insulin sensitivity.8 Thus, abdominal or central obesity
(which is more common in men than women) is clearly a
target for intervention.
Obesity and inflammation
In adipose tissues, fat-laden adipocytes attract macrophages
and initiate a vicious cycle of inflammation.9 Plasma
C-reactive protein (CRP), an inflammatory marker,
increases with obesity, even in children10; losing weight
reduces it. Elevated CRP levels are predictive of future
development of diabetes and cardiovascular events.11
Adipocytes also secrete tumour necrosis factor alpha
and plasminogen activator inhibitor-1.8 Inflammation in
adipose tissues is, therefore, an early event in the cardiovas-
cular continuum, preceding the development of diabetes,
endothelial dysfunction, and atherosclerotic disease. An
increase in pro-inflammatory cytokines and a decrease in
adiponectin may lead to endothelial dysfunction and facili-
tate the development of hypertension and atherosclerosis.
Diet and obesity
Obesity is caused by calorie intake in excess of energy
requirements. In modern, urban society, automation and the
ready availability and commercial promotion of foods with
high energy content all contribute to weight gain. Exercise
reduces body weight and reverses endothelial dysfunction,12
but the amount of exercise recommended in the latest
WHO directive13 (at least 30 minutes each day) is often not
feasible without profound changes in lifestyle, such as
fewer social engagements, and less television viewing
and internet use. Publications in leading journals suggest
that the current recommendation of a low-fat high-
carbohydrate diet may be wrong: a low carbohydrate diet
is more effective than a low-fat diet in inducing weight
loss.14 Dr Atkins was right: one can eat steaks and lose
weight effectively. Surprisingly, a low carbohydrate diet
will significantly raise high density lipoprotein–cholesterol
but not low density lipoprotein–cholesterol, and will reduce
plasma triglycerides and CRP.15
Not all carbohydrates are equally bad. The concept of
the glycaemic index is useful and is directly relevant to
diabetes and the metabolic syndrome. Foods with high
glycaemic indices are undesirable because a high blood
glucose peak stimulates insulin secretion, causing hunger a
few hours later.16 Foods with low glycaemic indices release
glucose more gradually. In a study in laboratory animals
comparing diets of low and high glycaemic indices with the
same total calories, rats and mice weighed the same in both
groups, but the animals fed the high glycaemic index diet
had twice as much body fat and a lower lean body mass.17
Polished rice, the staple food in much of Asia, is low
in fibre with a high glycaemic index ranging from 50 to 94,
depending on the variety of rice and how it is cooked.
Congee, popularly believed to be a healthy food item, can
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cause a particularly high peak in plasma glucose. Rice-based
meals have a place in rural societies where people walk a
lot and perform manual labour. To take a traditional
Asian example, Sumo wrestlers have a lot of subcutaneous
fat, but have little visceral fat because of heavy exercise.
However, the appropriateness of such a diet for an urban-
ised society is now questionable. The Chinese diet, with
low fat content and an abundance of green vegetables
and rice, is comparable with the Mediterranean diet in
healthiness. Paradoxically, Chinese populations have a very
high incidence of impaired glucose tolerance. In the Hong
Kong Cardiovascular Risk Factor Prevalence Survey-2
(CRISPS2) cohort,18 one third of those who were over the
age of 65 years had diabetes. A nutritional survey of the
same cohort showed that the intake of rice and pasta
was higher in diabetics of normal body weight.19 Thus
obesity and insulin resistance in much of Asia are not due
to excess fat in the diet, but to carbohydrate intake in
excess of energy expenditure requirements (Fig).
A new paradigm
Hypertension, diabetes, dyslipidaemia, and obesity need
not be treated in different clinics using different sets of
drugs. Obesity is at the centre of the metabolic syndrome
and should be treated as seriously as hypertension and
diabetes. Treatment of obesity not only reduces body
weight, but also waist circumference, blood pressure,
plasma glucose, and lipids. In theory, a change in diet
should work; lifestyle changes have been shown to prevent
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Fig. The cardiovascular continuum
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hypertension and diabetes.6,20 A “polymeal” has been
proposed as an alternative to the “polypill” to prevent
cardiovascular disease through nutrition rather than
drugs.21 In practice, however, therapeutic lifestyle changes
are plagued by poor compliance and high drop-out rates.
There are only five drugs currently approved by US
Food and Drug Administration for the treatment of obesity,
orlistat and sibutramine being the most widely used. If
people cannot change their dietary habits, then drugs are
needed to combat excess carbohydrates in the same way
statins are used in hypercholesterolaemia. This is an area
that urgently requires intensive research, as the epidemic
of obesity is happening here and now. We can start by
discarding the food pyramid, which, rather like those other
pyramids in Egypt, is now of mainly historical interest. The
US Department of Agriculture has now replaced the food
pyramid with My Pyramid (http://www.mypyramid.gov),
which is a step in the right direction to address the problem
of obesity and cardiovascular health.
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